ATA11842004A - Impfstoff gegen die alzheimer-krankheit - Google Patents

Impfstoff gegen die alzheimer-krankheit

Info

Publication number
ATA11842004A
ATA11842004A AT0118404A AT11842004A ATA11842004A AT A11842004 A ATA11842004 A AT A11842004A AT 0118404 A AT0118404 A AT 0118404A AT 11842004 A AT11842004 A AT 11842004A AT A11842004 A ATA11842004 A AT A11842004A
Authority
AT
Austria
Prior art keywords
alzheimer disease
vaccine against
vaccine
alzheimer
disease
Prior art date
Application number
AT0118404A
Other languages
English (en)
Other versions
AT413946B (de
Original Assignee
Mattner Frank Dr
Schmidt Walter Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mattner Frank Dr, Schmidt Walter Dr filed Critical Mattner Frank Dr
Priority to AT0118404A priority Critical patent/AT413946B/de
Priority to TW094120197A priority patent/TWI353848B/zh
Priority to JP2007520814A priority patent/JP5179866B2/ja
Priority to KR1020077002209A priority patent/KR101228409B1/ko
Priority to US11/630,679 priority patent/US8022180B2/en
Priority to EP05769807A priority patent/EP1765390A2/de
Priority to CA002573424A priority patent/CA2573424A1/en
Priority to PCT/EP2005/053225 priority patent/WO2006005707A2/en
Priority to CNA2005800306410A priority patent/CN101043901A/zh
Priority to CN2012105573960A priority patent/CN103263664A/zh
Priority to AU2005261688A priority patent/AU2005261688B2/en
Publication of ATA11842004A publication Critical patent/ATA11842004A/de
Application granted granted Critical
Publication of AT413946B publication Critical patent/AT413946B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0118404A 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit AT413946B (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit
TW094120197A TWI353848B (en) 2004-07-13 2005-06-17 Mimotope peptide,composition,and immunogenic compo
KR1020077002209A KR101228409B1 (ko) 2004-07-13 2005-07-06 알츠하이머 질환의 예방 및 치료 방법
US11/630,679 US8022180B2 (en) 2004-07-13 2005-07-06 Method for preventing and treating Alzheimer's disease
JP2007520814A JP5179866B2 (ja) 2004-07-13 2005-07-06 アルツハイマー病の予防および治療方法
EP05769807A EP1765390A2 (de) 2004-07-13 2005-07-06 Verfahren zur vorbeugung und behandlung der alzheimer-krankheit
CA002573424A CA2573424A1 (en) 2004-07-13 2005-07-06 Method for preventing and treating alzheimer´s disease
PCT/EP2005/053225 WO2006005707A2 (en) 2004-07-13 2005-07-06 Method for preventing and treating alzheimer´s disease
CNA2005800306410A CN101043901A (zh) 2004-07-13 2005-07-06 预防和治疗阿尔茨海默病的方法
CN2012105573960A CN103263664A (zh) 2004-07-13 2005-07-06 预防和治疗阿尔茨海默病的方法
AU2005261688A AU2005261688B2 (en) 2004-07-13 2005-07-06 Method for preventing and treating Alzheimer´s disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit

Publications (2)

Publication Number Publication Date
ATA11842004A true ATA11842004A (de) 2005-11-15
AT413946B AT413946B (de) 2006-07-15

Family

ID=35406000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0118404A AT413946B (de) 2004-07-13 2004-07-13 Impfstoff gegen die alzheimer-krankheit

Country Status (10)

Country Link
US (1) US8022180B2 (de)
EP (1) EP1765390A2 (de)
JP (1) JP5179866B2 (de)
KR (1) KR101228409B1 (de)
CN (2) CN101043901A (de)
AT (1) AT413946B (de)
AU (1) AU2005261688B2 (de)
CA (1) CA2573424A1 (de)
TW (1) TWI353848B (de)
WO (1) WO2006005707A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
CA2822302A1 (en) * 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
KR100820164B1 (ko) 2007-03-31 2008-04-08 한국전기연구원 피부질환 치료용 레이저 장치
KR100815483B1 (ko) 2007-05-09 2008-03-20 한국전기연구원 비등방성 레이저 결정을 이용한 다이오드 펌핑된 레이저장치
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8586706B2 (en) * 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CN102123726A (zh) * 2008-06-12 2011-07-13 阿费里斯股份公司 用于治疗与帕金森氏病有关的症状的化合物
US20130084245A1 (en) 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
KR101849975B1 (ko) * 2011-01-17 2018-05-31 삼성전자주식회사 음극, 음극 활물질, 음극의 제조방법 및 이를 채용한 리튬 전지
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
KR20140068105A (ko) * 2011-12-29 2014-06-05 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용
EP2659908A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP2787347A1 (de) 2013-04-03 2014-10-08 Affiris AG Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
KR102460465B1 (ko) * 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3911389B1 (de) 2019-01-14 2023-03-01 Philip Morris Products, S.A. Trockenpulverinhalatorvorrichtung
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung
EP4486389A1 (de) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG Konjugat mit mindestens einem beta-glucan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
AU784568B2 (en) * 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
EA007452B1 (ru) 2002-04-12 2006-10-27 Пи Джи Рисерч Фаундейшн, Инк. Многоколоночный генератор с инверсией избирательности для производства сверхчистых радионуклидов
JP2004016282A (ja) 2002-06-12 2004-01-22 Olympus Corp 内視鏡用画像処理装置
EP2338510A1 (de) * 2002-07-19 2011-06-29 Novartis Pharma AG Impfstoffzusammensetzungen, die Amyloid-beta1-6 Antigen-Arrays enthalten
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit

Also Published As

Publication number Publication date
CN101043901A (zh) 2007-09-26
TW200602071A (en) 2006-01-16
US8022180B2 (en) 2011-09-20
KR20070032033A (ko) 2007-03-20
WO2006005707A3 (en) 2006-08-17
CN103263664A (zh) 2013-08-28
CA2573424A1 (en) 2006-01-19
AT413946B (de) 2006-07-15
JP5179866B2 (ja) 2013-04-10
TWI353848B (en) 2011-12-11
JP2008506666A (ja) 2008-03-06
AU2005261688B2 (en) 2010-11-11
US20090004210A1 (en) 2009-01-01
AU2005261688A1 (en) 2006-01-19
EP1765390A2 (de) 2007-03-28
WO2006005707A2 (en) 2006-01-19
KR101228409B1 (ko) 2013-01-31

Similar Documents

Publication Publication Date Title
ATA11842004A (de) Impfstoff gegen die alzheimer-krankheit
DK1959991T3 (da) Terapeutisk vaccine
DK1968631T3 (da) Vaccine
DE502004003234D1 (de) Gegen missbrauch gesicherte darreichungsform
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
NO20054608D0 (no) Influensavirusvaksine
DK1957528T3 (da) Nukleotid-vaccine
ATE515515T1 (de) Immunglobuline gegen menschlisches osm
DE602005010597D1 (de) Bildaufzeichnungsverfahren
ATE432082T1 (de) Impfstoff gegen periodontale krankheit
ATE506362T1 (de) 1-aza-bicycloä3.3.1ünonane
DE502005007457D1 (de) Mikroemulsionen
DK1957073T3 (da) Lægemiddel
NL1031626A1 (nl) Verbindingen die bruikbaar zijn in therapie.
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
EP1807116A4 (de) Grippeimpfung
IS8325A (is) Bóluefni
EP1948782A4 (de) Impfstoffadjuvantien
DE602005003524D1 (de) Biegevorrichtung
DK1660123T3 (da) Rotavirusvaccine
DE602005024139D1 (de) Die anzeigevorrichtung
DK1877549T3 (da) HIV-vaccine
DE602006014799D1 (de) Heilmittel gegen sensorische erkrankungen
ES1058102Y (es) Lentilla terapeutica.
ES2365717T5 (es) Vacunacion meningococica conjugada.

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20151115